Evidence map›Paper›PMID 23532855›Full record

ArticleThe Journal of biological chemistry2013

Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters.

Berta Bosch, Erica L Heipertz, James R Drake, Paul A Roche

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 55 citations in OpenAlex.

  1. Regulatory T cells: From Foxp3 to tolerance-inducing therapies.The Journal of investigative dermatology · 2026
    Review
  2. Article
  3. Article
  4. Galectin-9 binding to HLA-DR in dendritic cells controls immune synapse formation and T cell proliferation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Lipid metabolism in dendritic cell biology.Immunological reviews · 2023
    Review
  9. Article
  10. Tetraspanin-5-mediated MHC class I clustering is required for optimal CD8 T cell activation.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  11. Article
  12. Article
  13. FcγRIIb on CD11cAtherosclerosis · 2019
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Engineering Platforms for T Cell Modulation.International review of cell and molecular biology · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Berta BoschExperimental Immunology Branch, NCI, National Institutes of Health, Bethesda, MD 20892, USA.
Erica L Heipertz
James R Drake
Paul A Roche
National Institutes of Health · USAlbany Medical Center Hospital · US

Funding

Regulation of MHC Class II Trafficking in Antigen Presenting CellsZIABC009404 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROCHE, PAUL · 2009 to 2025
$17.9M
Mechanisms of MHC Class II Association with Plasma Membrane MicrodomainsZIABC011033 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROCHE, PAUL · 2009 to 2020
$3.4M
Establishing the Molecular Mechanisms of BCR EndocytosisR01AI065773 · NIAID · ALBANY MEDICAL COLLEGE · PI DRAKE, JAMES R · 2007 to 2011
$1.9M
Intramural NIH HHSNIAID NIH HHS AI-065773NIAID NIH HHS R01 AI065773
6 · The paper itself

Abstract

backgroundAntigen-specific CD4 T cells are activated by small numbers of antigenic peptide-MHC class II (pMHC-II) complexes on dendritic cells (DCs).

resultsNewly generated pMHC-II complexes are present in small clusters on the DC surface.

conclusionpMHC-II clusters permit efficient T cell activation. SIGNIFICANCE: The appearance of clustered pMHC-II reveals the organization of the T cell antigen receptor ligand on the DC surface. Dendritic cells (DCs) function by stimulating naive antigen-specific CD4 T cells to proliferate and secrete a variety of immunomodulatory factors. The ability to activate naive T cells comes from the capacity of DCs to internalize, degrade, and express peptide fragments of antigenic proteins on their surface bound to MHC class II molecules (MHC-II). Although DCs express tens of thousands of distinct MHC-II, very small amounts of specific peptide-MHC-II complexes are required to interact with and activate T cells. We now show that stimulatory MHC-II I-A(k)-HEL(46-61) complexes that move from intracellular antigen-processing compartments to the plasma membrane are not randomly distributed on the DC surface. Confocal immunofluorescence microscopy and quantitative immunoelectron microscopy reveal that the majority of newly generated MHC-II I-A(k)-HEL(46-61) complexes are expressed in sub-100-nm microclusters on the DC membrane. These microclusters are stabilized in cholesterol-containing microdomains, and cholesterol depletion inhibits the stability of these clusters as well as the ability of the DCs to function as antigen-presenting cells. These results demonstrate that specific cohorts of peptide-MHC-II complexes expressed on the DC surface are present in cholesterol-dependent microclusters and that cluster integrity is important for antigen-specific naive CD4 T cell activation by DCs.

Indexed as

AnimalsAntigen PresentationAntigensCD4-Positive T-LymphocytesCell MembraneCells, CulturedCholesterolDendritic CellsHistocompatibility Antigens Class IILymphocyte ActivationMembrane LipidsMembrane MicrodomainsMiceMice, TransgenicProtein TransportAntigensCholesterolHistocompatibility Antigens Class IIMembrane LipidsDendritic CellsLipid RaftMajor Histocompatibility Complex (MHC)Membrane TraffickingT Cell

Identifiers

PMID23532855
PMCPMC3650363
OpenAlexW1978665494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.